Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors.
Koda RT, Garcia AA, Chatterjee DJ, Li WY, Parimoo D, Jeffers S, Rogers M, Leichman CG, Leichman L, Wu EY, Shetty BV, Webber S, Clendinnin N, Muggia FM.
Koda RT, et al. Among authors: muggia fm.
Cancer Chemother Pharmacol. 1999;43(6):489-96. doi: 10.1007/s002800050928.
Cancer Chemother Pharmacol. 1999.
PMID: 10321509
Clinical Trial.